GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3

Cancer Research

Volumn 74, Issue 9, 2014, Pages 2604-2616

  Fabian, Johannes ^a   Lodrini, Marco ^a   Oehme, Ina ^a   Schier, Marie C ^a   Thole, Theresa M ^a   Hielscher, Thomas ^b   Kopp Schneider, Annette ^b   Opitz, Lennart ^e   Capper, David ^b,c   Von Deimling, Andreas ^b,c   Wiegand, Inga ^a   Milde, Till ^a,d   Mahlknecht, Ulrich ^f   Westermann, Frank ^b   Popanda, Odilia ^a   Roels, Frederik ^b,g   Hero, Barbara ^b   Berthold, Frank ^b   Fischer, Matthias ^b,g   Kulozik, Andreas E ^d   Witt, Olaf ^a,d   Deubzer, Hedwig E ^a,d   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Department of Biostatistics ^*  (Germany)

^c Clinical Cooperation Unit Neuropathology   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f St Lukas Klinik gGmbH   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABEXINOSTAT; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; PANOBINOSTAT; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; COLONY FORMATION; ENZYME ACTIVITY; FEMALE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE LOCATION; GENE REPRESSION; GENE SILENCING; GENETIC SCREENING; GRAINYHEAD LIKE 1 GENE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; INFANT; KAPLAN-MEIER ESTIMATE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TUMOR BURDEN;

EID: 84899997871     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1904     Document Type: Article

References (45)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16
2. Tonini GP, Nakagawara A, Berthold F. Towards a turning point of neuroblastoma therapy. Cancer Lett 2012;326:128-34
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas- Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13
4. Hobbie WL, Moshang T, Carlson CA, Goldmuntz E, Sacks N, Goldfarb SB, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008; 51:679-83
5. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 2006;18: 634-8
6. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8
7. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13: 803-12
8. Galderisi U, Di Bernardo G, Cipollaro M, Peluso G, Cascino A, Cotrufo R, et al. Differentiation and apoptosis of neuroblastoma cells: role of Nmyc gene product. J Cell Biochem 1999;73:97-105
9. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B, et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 1997;8:958-63
10. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27- 275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-15
11. Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008;122:1891-900
12. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013;41:6018-33
13. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009;15:91-9
14. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A 2013;110:E2592-601
15. Bayraktar OA, Doe CQ. Combinatorial temporal patterning in progenitors expands neural diversity. Nature 2013;498:449-55
16. Oberthuer A, Juraeva D, Li L, Kahlert Y, Westermann F, Eils R, et al. Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. Pharmacogenomics J 2010;10:258-66
17. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-15
18. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483:589-93
19. Schmitt M, Pawlita M. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 2009;37:e119
20. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M. High-throughput SNP-based authentication of human cell lines. Int J Cancer 2013;132:308-14
21. Fischer M, Skowron M, Berthold F. Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 2005; 7:89-96.
22. Lausen B, Sauerbrei W, Schumacher P. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales. In: Computational Statistics. Contributions to Statistics. Physica Verlag 1994;483-496
23. Deubzer HE, Lodrini M, Schier MC, Oehme I, Schulte JH, Thole TM, et al. HDAC11 transcriptionally represses BMP4 to promote neuroblastoma malignancy. Manuscript in preparation
24. HendersonYC, Frederick MJ,WangMT,Hollier LM, Clayman GL. LBP- 1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation. DNA Cell Biol 2008;27:71-9
25. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8:138-40
26. Nozato M, Kaneko S, Nakagawara A, Komuro H. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma. Int J Oncol 2013;42:134-40
27. Schultz A, Jonsson JI, Larsson C. The regulatory domain of protein kinase Ctheta localises to the Golgi complex and induces apoptosis in neuroblastoma and Jurkat cells. Cell Death Differ 2003;10:662-75
28. Gustavsson P, Copp AJ, Greene ND. Grainyhead genes and mammalian neural tube closure. Birth Defects Res A Clin Mol Teratol 2008; 82:728-35
29. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 2013;45:12-7
30. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012;307:1062-71
31. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013;45:279-84
32. Nüsslein-Volhard C, Wieschaus E, Kluding H. Mutations affecting the pattern of the larval cuticle in Drosophila melangogaster. Wilhelms Roux's Arch Dev 1984;267-282
33. Maurange C, Cheng L, Gould AP. Temporal transcription factors and their targets schedule the end of neural proliferation in Drosophila. Cell 2008;133:891-902
34. Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, et al. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Cell Death Differ 2011;18:1174-83
35. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, Rycak L, et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-Myc in childhood neuroblastoma. Cancer Cell 2013;24: 75-89
36. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55: 26-34
37. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3:308-23
38. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, et al. Transcriptional upregulation of histone deacetylase 2 promotes Mycinduced oncogenic effects. Oncogene 2010;29:5957-68
39. Kim MK, Carroll WL. Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. Cancer 2004;101: 2106-15
40. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, et al.ASP1/MIZ1/ MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res 2011;71:404-12
41. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci U S A 2007;104:18682-7
42. Kurland JF, Tansey WP. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 2008;68: 3624-9
43. Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012;31:3002-8
44. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012;22:506-23
45. Lawlor ER, Thiele CJ. Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res 2012;18:2768-79.